RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
RedHill Biopharma (RDHL) Tops Q3 EPS by 21c, Revenues Miss
November 12, 2020 7:03 AM ESTRedHill Biopharma (NASDAQ: RDHL) reported Q3 EPS of $0.05, $0.21 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $25.37 million.
Financial highlights for the third quarter ended September 30, 20201
Net Revenues of $20.9 million, continuing at a similar level to that in the second quarter of 2020. The increase in gross revenues, as well as in the number of scripts for Talicia and Movantik, were partially offset by the voluntary discontinuation of our legacy products.Cost of Revenues of $10.3 million, compared to $14.2 million in the... More